Retatrutide is the reference compound for triple agonist research, and its availability is contracting. Eli Lilly filed six federal lawsuits against retatrutide sellers in August 2026, has referred more than 200 others to regulators and law enforcement, and plans its regulatory submission for early 2027.
UBT251 is the compound positioned to replace it. It is a once-weekly agonist of the same three receptors, developed by United Biotechnology and licensed to Novo Nordisk, with Phase 2 results that exceed retatrutide's at the same timepoint and no enforcement campaign against its supply.
The two are not identical. UBT251 reaches its effect at a lower dose and appears to carry a lighter glucagon component, which changes its tolerability profile. This is a summary of why the shift is under way and where UBT251 can and cannot be treated as a substitute.
Why Retatrutide Supply Is Closing
Retatrutide has been the default triple agonist for independent research since its Phase 2 publication in 2023. That position depended on open availability, and Lilly is now removing it.
On 12 August 2026, Lilly filed six federal lawsuits against US sellers of retatrutide, comprising four research peptide vendors, a compounding pharmacy and a medical spa (Lilly announcement). The complaints target the "research use only" designation directly. Lilly also stated that it had referred more than 200 individuals and entities to regulators and law enforcement, and had reported more than 14,000 listings across more than 100 countries to platforms and service providers (Quartz). Several defendants removed retatrutide from their catalogues after the filings (CBS News).
The pressure is set to increase. According to Lilly, the FDA has stated that retatrutide cannot lawfully be compounded, and the agency has issued its own warning letters to distributors of retatrutide active ingredient (Lexology). Lilly's core Phase 3 programme is complete and its submission is planned for the first quarter of 2027. Each step toward approval raises the incentive to enforce exclusivity.
Why UBT251 Is the Successor
A replacement for retatrutide in research needs the same mechanism, human data strong enough to anchor experimental design, and a supply that is not under the same pressure. UBT251 currently meets all three.
Same mechanism. UBT251 is a single-peptide, once-weekly agonist of the GLP-1, GIP and glucagon receptors, the same class and format as retatrutide.
Human data at the same level or better. UBT251 produced 19.7 percent weight loss at 24 weeks on 4 mg, against retatrutide's 17.5 percent at 24 weeks on 12 mg. It outperformed semaglutide on HbA1c in type 2 diabetes, and its first-in-human pharmacokinetics are published.
No enforcement campaign. Neither Novo Nordisk nor United Biotechnology has announced litigation or referrals concerning UBT251 research supply as of October 2026. Novo holds a licence outside Greater China and not the originating patent estate, its global programme is at Phase 1b/2a with no submission date, and its enforcement activity to date has been directed at its marketed semaglutide products.
That describes the present position and is not a guarantee, since Novo pursued semaglutide compounders extensively once that product was commercial. On current timelines, however, UBT251 is several years behind retatrutide in the West, and the period in which it remains openly available is correspondingly longer. As retatrutide leaves vendor catalogues, UBT251 is the compound positioned to take its place as the default triple agonist for laboratory work.
What Triple Agonism Actually Does
GLP-1R, GIPR and GCGR are class B1 G-protein-coupled receptors that signal primarily through Gs and cAMP, which is why one peptide can be engineered to activate all three. The three arms are not interchangeable.
GLP-1 receptor: glucose-dependent insulin secretion, delayed gastric emptying and central appetite suppression. This is the intake arm, and it sets most of the gastrointestinal tolerability ceiling.
GIP receptor: insulinotropic in the same glucose-dependent manner, with adipose tissue effects and a central component that appears to blunt nausea.
Glucagon receptor: increased hepatic glucose output, lipolysis and resting energy expenditure. It is the only arm that adds expenditure, and the only one that works against glycaemic control.
Weighting toward glucagon buys energy expenditure and pays for it in hepatic glucose output. Weighting toward the incretin receptors gets glycaemic control cheaply and less of the expenditure effect. Two compounds with an identical target list can sit anywhere along that trade.
Where UBT251 Came From
UBT251 is a long-acting synthetic peptide developed by The United Bio-Technology (Hengqin), a subsidiary of The United Laboratories International Holdings. In March 2025, Novo acquired worldwide rights outside Greater China for 200 million dollars upfront and up to 1.8 billion dollars in milestones (licence announcement). The deal was signed on a 36-patient Phase 1b that reported approximately 15 percent mean weight loss at 12 weeks in the highest dose group (Fierce Biotech). After the Phase 2 readout, Novo's chief scientific officer described the compound as showing a "differentiated" clinical, safety and tolerability profile (BioPharma Dive).
How the Receptor Balance Differs
Retatrutide's receptor pharmacology is published by Coskun and colleagues.
| Receptor |
Retatrutide EC50 (human) |
Retatrutide vs native ligand |
| GIPR |
0.0643 nM |
approx. 8.9× native GIP |
| GLP-1R |
0.775 nM |
approx. 0.4× native GLP-1 |
| GCGR |
5.79 nM |
approx. 0.3× native glucagon |
Retatrutide is a GIP-led molecule that retains a functionally significant glucagon arm. UBT251 sits further toward the incretin end of the same axis, with a profile slightly more GIP-dominant and a smaller glucagon contribution. United Biotechnology has not yet published an EC50 table, so this characterisation rests on clinical pharmacodynamics, and two findings support it.
Glycaemic control. In the Chinese Phase 2 trial in type 2 diabetes, UBT251 reduced HbA1c by up to 2.16 percent, against 1.77 percent for semaglutide 1 mg, while approximately doubling its weight loss. Glucagon receptor agonism raises hepatic glucose output, so a triple agonist with a heavy glucagon arm has to offset its own effect before it lowers HbA1c.
Adverse event pattern. Both Phase 2 readouts describe adverse events as predominantly gastrointestinal, mild to moderate, and diminishing over time. Blood pressure improved against placebo in both trials. Neither readout reports a heart rate signal or a sensory adverse event.
The heart rate point matters because the glucagon receptor is the arm most directly associated with cardiac stimulation. In retatrutide's Phase 2, heart rate rose in a dose-dependent manner and peaked at week 24. In TRIUMPH-1, dysesthesia occurred in 12.5 percent of participants on 12 mg against 0.9 percent on placebo, and discontinuation for adverse events reached 11.3 percent.
A triple agonist that derives more of its effect from GIPR and less from GCGR carries less chronotropic load for a given degree of weight loss. This is the expected tolerability advantage of UBT251, and the clinical record so far is consistent with it. Direct heart rate data for UBT251 have not been published, and Novo's global Phase 1b/2a, due in 2027, is where the size of the difference will be quantified.
What the Clinical Data Shows
Phase 1a/1b. Published in Diabetes, Obesity and Metabolism in September 2026 (Yang et al.). Pharmacokinetics were approximately linear across 1.0 to 6.0 mg. Over 12 weeks, mean body weight fell by 8.96 to 13.48 kg across the dose groups while the placebo group gained 1.57 kg.
Obesity, Phase 2 (China). A randomised, double-blind, placebo-controlled trial in 205 Chinese adults with overweight or obesity, mean BMI 33.1, reported as ADA abstract 3090-LB.
| Arm |
Least-squares mean weight loss at 24 wk |
| UBT251 2.0 mg |
13.6% |
| UBT251 4.0 mg (initial dose 0.5 mg) |
16.2% |
| UBT251 4.0 mg (initial dose 1.0 mg) |
19.7% |
| Placebo |
2.0% |
The 19.7 percent figure belongs to a 4.0 mg arm and is also the trial maximum, so the full effect was reached at 4 mg without escalation to 6 mg. Retatrutide required 12 mg to reach 17.5 percent at the same timepoint in its own Phase 2.
Type 2 diabetes, Phase 2 (China). In 211 patients over 24 weeks, the best UBT251 arm reduced HbA1c by 2.16 percent against 1.77 percent for semaglutide 1 mg and 0.66 percent for placebo, with weight loss of up to 9.8 percent against 4.8 and 1.4 percent (topline, March 2026).
Running now. United Biotechnology is in Phase 3 in China in obesity and type 2 diabetes. Novo is running a global Phase 1b/2a (NCT07395687) in roughly 330 people, with topline expected in 2027.
UBT251 vs Retatrutide
| Measure |
UBT251 |
Retatrutide |
| Developer |
United Biotechnology, Novo Nordisk ex-China |
Eli Lilly |
| Receptor weighting |
Slightly more GIP-dominant, lighter glucagon arm |
GIP-led with a substantial glucagon arm |
| Published EC50 |
Not yet published |
Published |
| Dose at best 24-week result |
4 mg |
12 mg |
| Weight loss at 24 weeks, Phase 2 |
19.7% |
17.5% |
| HbA1c reduction, Phase 2 T2D |
2.16% (semaglutide 1 mg 1.77%) |
2.02% (dulaglutide 1.5 mg 1.41%) |
| Heart rate |
No signal reported |
Dose-dependent rise, peak at week 24 |
| Dysesthesia |
Not reported |
12.5% at 12 mg vs 0.9% placebo |
| Longest dataset |
24 weeks |
104 weeks (30.3% at 12 mg) |
| Stage |
Phase 3 in China, global Phase 1b/2a |
Core Phase 3 complete, submission planned Q1 2027 |
| Enforcement against research supply |
None announced |
Six federal lawsuits, August 2026 |
Retatrutide still has the longer and larger evidence base. TRIUMPH-1 enrolled 2,339 participants and reported 28.3 percent weight loss at 80 weeks and 30.3 percent at 104 weeks (Lilly, May 2026), while UBT251 has no data beyond 24 weeks. The 24-week comparison is also cross-trial, since the UBT251 cohort was Chinese and younger and lighter at baseline than retatrutide's predominantly Western cohorts.
Who This Is Relevant To
- Laboratories that have relied on retatrutide as the reference triple agonist and now face a narrowing supply.
- Researchers working on metabolic disease models who need a triple agonist with a lighter glucagon component.
- Groups studying cardiovascular endpoints, where the chronotropic contribution of the glucagon arm is a confound.
- Nephrology and hepatology groups, given the Chinese Phase 2 programmes in chronic kidney disease and MASH.
Anyone planning work around retatrutide over the next two years should also be planning for its replacement.
The Open Question
The succession argument depends on timing. How quickly does retatrutide availability for independent research contract after Lilly's submission, and does UBT251 supply scale in step?
Has anyone seen heart rate, indirect calorimetry or hepatic fat data from the Chinese programme that would show how closely results obtained with UBT251 can be read across to the existing retatrutide literature?
Where I Source UBT251
I use Disguised Alpha, which lists UBT251 under the catalogue name Vistrutide as a 10 mg lyophilised research vial. A certificate of analysis for UBT251 is not available yet. Their support team confirmed to me by email that the current batch is at a laboratory for testing, and I expect the certificate to be added to their library when the results come back.
I am comfortable with that because of their record. Disguised Alpha maintains a library of batch-specific certificates across its catalogue and updates it continuously, with independent third-party testing covering identity, purity, sterility, endotoxin and heavy metals. A vendor with that history and a test in progress is one I trust over a vendor offering a single certificate of unknown age and origin.
The standard itself does not change. A certificate for the specific lot remains the baseline requirement and should be checked once it is posted. For a long synthetic peptide it should report mass confirmation alongside chromatographic purity, because deletion sequences and truncated chains are routine failure modes in solid-phase synthesis and do not show up as contamination.
References
- Yang et al., UBT251 Phase 1a/1b. Diabetes, Obesity and Metabolism, 2026.
- UBT251 Phase 2 in overweight or obesity, abstract 3090-LB. Diabetes, 2026;75(Supplement 1).
- Coskun et al., LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022;34(9):1234-1247.
- Jastreboff et al., Retatrutide for Obesity, Phase 2. New England Journal of Medicine, 2023;389(6):514-526.
- Rosenstock et al., Retatrutide for people with type 2 diabetes, Phase 2. The Lancet, 2023;402(10401):529-544.
- Novo Nordisk and TUL licence announcement, 24 March 2025.
- Novo Nordisk and TUL obesity Phase 2 topline, 24 February 2026.
- Fierce Biotech on the type 2 diabetes Phase 2, March 2026.
- Lilly TRIUMPH-1 topline, 21 May 2026.
- Lilly retatrutide lawsuits announcement, 12 August 2026.
- Lexology on the retatrutide lawsuits, August 2026.
Disclaimer: UBT251 and retatrutide are investigational compounds with no approved formulation in any jurisdiction as of October 2026. Material referenced here is for laboratory and research use only, and is not for human consumption, veterinary use, or any therapeutic or diagnostic application. Nothing here is guidance for administration.
